Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) - Full Text View

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00000488

Purpose

To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men.

Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown.

Condition	Intervention	Phase
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia	Drug: cholestyramine Behavioral: diet, fat-restricted	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind

Resource links provided by NLM:

MedlinePlus related topics: Coronary Artery Disease Diets Heart Diseases

Drug Information available for: Cholestyramine

U.S. FDA Resources

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:

June 1973

Show Detailed Description

Eligibility

Ages Eligible for Study:	35 Years to 59 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Men, ages 35-59. Type II hyperlipoproteinemia. Free from coronary heart disease.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000488

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigator:	Francois Abboud	University of Iowa
Investigator:	Elizabeth Barrett-Connor	University of California, San Diego
Investigator:	Reagan Bradford	Oklahoma Medical Research Foundation
Investigator:	Marilyn Buzzard	University of Minnesota
Investigator:	Gerald Cooper	Centers for Disease Control and Prevention
Investigator:	John Farquhar	Stanford University
Investigator:	Ivan Frantz	University of Minnesota
Investigator:	Anne Goldberg	Washington University School of Medicine
Investigator:	Frank Ibbott	Bio-Science Laboratories
Investigator:	William, Insull	Baylor College of Medicine
Investigator:	Robert Knoop	University of Washington
Investigator:	Peter Kwiterovich	Johns Hopkins University
Investigator:	John LaRosa	George Washington University
Investigator:	J. Little	University of Toronto
Investigator:	L. Sheffield	University of Alabama at Birmingham
Investigator:	Dennis Sprecher	University of Cincinnati

More Information

Publications:

[No authors listed] The coronary primary prevention trial: design and implementation: the Lipid Research Clinics Program. J Chronic Dis. 1979;32(9-10):609-31. No abstract available.

Agras WS, Marshall G. Recruitment for the Coronary Primary Prevention Trial. Clin Pharmacol Ther. 1979 May;25(5 Pt 2):688-90.

Rifkind B, Goor R: The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT). Drugs Affecting Lipid Metabolism, l5l-l57, Fumagalli R, Kritchevsky D, Paoletti R (Eds): Elsevier/North-Holland Biomedical Press, l980.

Knopp RH: Test of the Lipid Hypothesis: The Coronary Primary Prevention Trial (CPPT) of the Lipid Research Clinics Program. Proceedings of the Fifth International Symposium on Atherosclerosis, 509-512, Gotto, AM, Jr. (Ed.): Springer-Verlag, 1980.

[No authors listed] Recruitment for clinical trials: the Lipid Research Clinics Coronary Primary Prevention Trial experience. Its implications for future trials. Circulation. 1982 Dec;66(6 Pt 2):IV1-78. No abstract available.

Gordon DJ, Salz KM, Roggenkamp KJ, Franklin FA Jr. Dietary determinants of plasma cholesterol change in the recruitment phase of the Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis. 1982 Nov-Dec;2(6):537-48.

Gordon DJ, Witztum JL, Hunninghake D, Gates S, Glueck CJ. Habitual physical activity and high-density lipoprotein cholesterol in men with primary hypercholesterolemia. The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1983 Mar;67(3):512-20.

[No authors listed] Participant recruitment to the Coronary Primary Prevention Trial. J Chronic Dis. 1983;36(6):451-65.

[No authors listed] Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. J Chronic Dis. 1983;36(6):467-79.

[No authors listed] The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan 20;251(3):351-64.

[No authors listed] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan 20;251(3):365-74.

Rifkind BM. Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. Am J Cardiol. 1984 Aug 27;54(5):30C-34C.

Gordon DJ, Probstfield JL, Rubenstein C, Bremner WF, Leon AS, Karon JM, Third J, Bryan H, Schwartz L, Insull W, et al. Coronary risk factors and exercise test performance in asymptomatic hypercholesterolemic men: application of proportional hazards analysis. Am J Epidemiol. 1984 Aug;120(2):210-24.

[No authors listed] NHLBI workshop on the Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis. 1985 Jul-Aug;5(4):397-403. No abstract available.

Rifkind BM: The Lipid Research Clinics Coronary Primary Prevention Trial (CPPT). Heartbeat, 1:7-8, 1985.

Rifkind BM: The Lipid Research Clinics Coronary Primary Prevention Trial. In Shepherd G, et al (Eds). Lipoproteins and Coronary Heart Disease. London and Glasgow. Blantyre Printing Ltd.:109, 1986.

Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986 Dec;74(6):1217-25.

Glueck CJ, Gordon DJ, Nelson JJ, Davis CE, Tyroler HA. Dietary and other correlates of changes in total and low density lipoprotein cholesterol in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Am J Clin Nutr. 1986 Oct;44(4):489-500.

Probstfield JL, Russell ML, Henske JC, Reardon RJ, Insull W Jr. Successful program for recovery of dropouts to a clinical trial. Am J Med. 1986 May;80(5):777-84.

Gordon DJ, Leon AS, Ekelund LG, Sopko G, Probstfield JL, Rubenstein C, Sheffield LT. Smoking, physical activity, and other predictors of endurance and heart rate response to exercise in asymptomatic hypercholesterolemic men. The Lipid Research Clinics Coronary Primary Prevention Trial. Am J Epidemiol. 1987 Apr;125(4):587-600.

Knoke JD, Hunninghake DB, Heiss G. Physiological markers of smoking and their relation to coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis. 1987 Sep-Oct;7(5):477-82.

Bradford RH. Participant recruitment to the Lipid Research Clinics Coronary Primary Prevention Trial. Control Clin Trials. 1987 Dec;8(4 Suppl):31S-40S.

Gordon DJ, Trost DC, Hyde J, Whaley FS, Hannan PJ, Jacobs DR Jr, Ekelund LG. Seasonal cholesterol cycles: the Lipid Research Clinics Coronary Primary Prevention Trial placebo group. Circulation. 1987 Dec;76(6):1224-31.

Gordon DJ, Hyde J, Trost DC, Whaley FS, Hannan PJ, Jacobs DR, Ekelund LG. Cyclic seasonal variation in plasma lipid and lipoprotein levels: the Lipid Research Clinics Coronary Primary Prevention Trial Placebo Group. J Clin Epidemiol. 1988;41(7):679-89.

Brook JG, Rifkind BM: The Lipid Research Clinics Primary Prevention Trial and its Aftermath. In: Recent Aspects of Diagnosis and Treatment of Lipoprotein Disorders: Impact on Prevention of Atherosclerotic Disease. Alan R Liss Inc., 7-14, 1988.

Siscovick DS, Ekelund LG, Hyde JS, Johnson JL, Gordon DJ, LaRosa JC. Physical activity and coronary heart disease among asymptomatic hypercholesterolemic men (the Lipid Research Clinics Coronary Primary Prevention Trial). Am J Public Health. 1988 Nov;78(11):1428-31.

Ekelund LG, Suchindran CM, McMahon RP, Heiss G, Leon AS, Romhilt DW, Rubenstein CL, Probstfield JL, Ruwitch JF. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol. 1989 Sep;14(3):556-63.

Probstfield JL, Rifkind BM. The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications. Eur J Clin Pharmacol. 1991;40 Suppl 1:S69-75.

[No authors listed] The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med. 1992 Jul;152(7):1399-410.

Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994 Apr 6;271(13):999-1003.

Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA. 1994 Nov 9;272(18):1439-41.

Study ID Numbers:	7
Study First Received:	October 27, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000488 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Antimetabolites
Arterial Occlusive Diseases
Coronary Disease
Cholestyramine
Heart Diseases
Antilipemic Agents

Myocardial Ischemia
Vascular Diseases
Anticholesteremic Agents
Arteriosclerosis
Ischemia
Coronary Artery Disease

Additional relevant MeSH terms:

Antimetabolites
Arterial Occlusive Diseases
Cholestyramine
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Myocardial Ischemia
Antilipemic Agents
Vascular Diseases
Ischemia

Arteriosclerosis
Anticholesteremic Agents
Pharmacologic Actions
Coronary Disease
Pathologic Processes
Therapeutic Uses
Cardiovascular Diseases
Coronary Artery Disease

ClinicalTrials.gov processed this record on July 02, 2009